TY - JOUR
T1 - Chronic cerebrospinal venous insufficiency and multiple sclerosis
T2 - A comprehensive meta-analysis of case-control studies
AU - Tsivgoulis, Georgios
AU - Sergentanis, Theodoros N.
AU - Psaltopoulou, Theodora
AU - Chan, Andrew
AU - Gold, Ralf
AU - Krogias, Christos
AU - Voumvourakis, Konstantinos
AU - Triantafyllou, Nikos
N1 - Funding Information:
Dr Georgios Tsivgoulis has been supported by European Regional Development Fund - Project FNUSA-ICRC (No. Z.1.05/1.1.00/02.0123). Theodoros Sergentanis, Konstantinos Voumvourakis, Nikos Triantafyllou, Theodora Psaltopoulou and Christos Krogias have no disclosures. Andrew Chan received personal compensation as a speaker or consultant for Allmirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva Neuroscience. He received research support from the German Ministry for Education and Research (BMBF, ‘German Competence Network Multiple Sclerosis’ (KKNMS), CONTROL MS, 01GI0914), Bayer Schering, Biogen Idec, Merck Serono and Novartis. Ralf Gold has no project-specific disclosures but has received personal compensation and grant support from BiogenIdec, BayerSchering, Novartis, MerckSerono, Sanofi-Genzyme, Roche, TEVA.
PY - 2014/3
Y1 - 2014/3
N2 - Chronic cerebrospinal venous insufficiency (CCSVI) has recently been implicated in the pathogenesis of multiple sclerosis (MS). This comprehensive meta-analysis of case–control studies investigates the association of CCSVI with MS. Methods: Through Medline, EMBASE and Cochrane database searches, case–control ultrasound studies comparing CCSVI frequency among patients with MS and healthy controls were identified. Results: We identified 19 eligible studies including 1250 patients with MS and 899 healthy controls. The pooled analysis showed that CCSVI was associated with MS [odds ratio (OR) 8.35; 95% confidence interval (CI) 3.44–20.31; p < 0.001) with considerable heterogeneity across studies (I2 = 80.1%). This association was substantially attenuated in sensitivity analyses excluding studies that were carried out by the group that originally described CCSVI, included investigators who had also been involved in publications advocating endovascular procedures for CCSVI treatment, or were conducted in Italy. Our most conservative sensitivity analysis combining different exclusion criteria yielded no association of CCSVI with MS (OR 1.35; 95% CI 0.62–2.93; p = 0.453) without any heterogeneity (I2 = 0%). There is considerable heterogeneity across different case–control studies evaluating the association of CCSVI and MS. The greatest factor contributing to this heterogeneity appears to be the involvement of investigators in other publications supporting endovascular procedures as a novel MS treatment.
AB - Chronic cerebrospinal venous insufficiency (CCSVI) has recently been implicated in the pathogenesis of multiple sclerosis (MS). This comprehensive meta-analysis of case–control studies investigates the association of CCSVI with MS. Methods: Through Medline, EMBASE and Cochrane database searches, case–control ultrasound studies comparing CCSVI frequency among patients with MS and healthy controls were identified. Results: We identified 19 eligible studies including 1250 patients with MS and 899 healthy controls. The pooled analysis showed that CCSVI was associated with MS [odds ratio (OR) 8.35; 95% confidence interval (CI) 3.44–20.31; p < 0.001) with considerable heterogeneity across studies (I2 = 80.1%). This association was substantially attenuated in sensitivity analyses excluding studies that were carried out by the group that originally described CCSVI, included investigators who had also been involved in publications advocating endovascular procedures for CCSVI treatment, or were conducted in Italy. Our most conservative sensitivity analysis combining different exclusion criteria yielded no association of CCSVI with MS (OR 1.35; 95% CI 0.62–2.93; p = 0.453) without any heterogeneity (I2 = 0%). There is considerable heterogeneity across different case–control studies evaluating the association of CCSVI and MS. The greatest factor contributing to this heterogeneity appears to be the involvement of investigators in other publications supporting endovascular procedures as a novel MS treatment.
KW - chronic cerebrospinal venous insufficiency
KW - meta-analysis
KW - multiple sclerosis
KW - ultrasound
UR - http://www.scopus.com/inward/record.url?scp=84896819015&partnerID=8YFLogxK
U2 - 10.1177/1756285613499425
DO - 10.1177/1756285613499425
M3 - Review article
AN - SCOPUS:84896819015
SN - 1756-2856
VL - 7
SP - 114
EP - 136
JO - Therapeutic Advances in Neurological Disorders
JF - Therapeutic Advances in Neurological Disorders
IS - 2
ER -